We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Intensive care

15 October 2018 By Neil Unmack

The UK medical devices maker lost nearly 30 pct of its value after it warned of lower growth and its CEO resigned. The selloff seems excessive given modest changes to revenue and margins. The remedy could be cost cuts. But any turnaround will have to wait for a new chief.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)